Karyopharm Therapeutics Inc.
General ticker "KPTI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $58.2M (TTM average)
Karyopharm Therapeutics Inc. follows the US Stock Market performance with the rate: 3.0%.
Estimated limits based on current volatility of 4.6%: low 5.27$, high 5.78$
Factors to consider:
- Total employees count: 279 as of 2024
- Top business risk factors: Regulatory and compliance, Geopolitical risks, Operational and conduct risks, Trade tariffs, Market volatility
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.92$, 18.49$]
- 2025-12-31 to 2026-12-31 estimated range: [4.25$, 13.71$]
Financial Metrics affecting the KPTI estimates:
- Negative: with PPE of -0.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -161.35 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 120.83 > -0.66
- Negative: Shareholder equity ratio, % of -113.14 <= 18.93
Short-term KPTI quotes
Long-term KPTI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $157.07MM | $146.03MM | $145.24MM |
| Operating Expenses | $299.28MM | $275.57MM | $264.68MM |
| Operating Income | $-142.20MM | $-129.54MM | $-119.44MM |
| Non-Operating Income | $-22.72MM | $-13.24MM | $43.08MM |
| Interest Expense | $25.00MM | $23.82MM | $37.42MM |
| R&D Expense | $148.66MM | $138.75MM | $143.23MM |
| Income(Loss) | $-164.92MM | $-142.78MM | $-76.36MM |
| Taxes | $0.37MM | $0.32MM | $0.06MM |
| Profit(Loss)* | $-165.29MM | $-143.10MM | $-76.42MM |
| Stockholders Equity | $-16.66MM | $-136.21MM | $-186.02MM |
| Inventory | $4.22MM | $3.04MM | $4.74MM |
| Assets | $358.17MM | $240.44MM | $164.42MM |
| Operating Cash Flow | $-149.55MM | $-92.72MM | $-127.49MM |
| Capital expenditure | $0.12MM | $0.00MM | $0.14MM |
| Investing Cash Flow | $-104.26MM | $7.94MM | $95.47MM |
| Financing Cash Flow | $193.74MM | $1.12MM | $41.65MM |
| Earnings Per Share** | $-30.28 | $-18.79 | $-9.41 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.